Regarding the pathological features and risk factors of endometrial carcinoma, all of the following are true EXCEPT:

Explanation

## Endometrial Carcinoma: Pathological Classification and Risk Factors ### Type I vs Type II Endometrial Carcinoma | Feature | Type I | Type II | |---------|--------|--------| | **Histology** | Endometrioid adenocarcinoma (80–85%) | Serous, clear cell, undifferentiated | | **Molecular basis** | PTEN, KRAS, PIK3CA mutations | TP53 mutations (p53 pathway) | | **Precursor** | Endometrial intraepithelial neoplasia (EIN) | Atypical endometrial polyp / serous intraepithelial carcinoma (SEIC) | | **Risk factors** | Unopposed estrogen, obesity, PCOS, metabolic syndrome | Age, smoking, prior pelvic radiation | | **Stage at presentation** | Early (I–II) | Advanced (III–IV) | | **Prognosis** | Better (5-year survival ~80%) | Worse (5-year survival ~30%) | **Key Point:** Type I carcinomas account for ~80% of endometrial cancers and are estrogen-dependent; Type II are aggressive, estrogen-independent, and account for ~10% but cause disproportionate mortality. ### Tamoxifen and Endometrial Risk **High-Yield:** Tamoxifen is a selective estrogen receptor modulator (SERM). In the breast, it acts as an antagonist; in the endometrium, it acts as an **agonist**, producing an estrogenic effect. This increases endometrial carcinoma risk 2–3-fold in breast cancer survivors — it does NOT provide a protective effect. **Clinical Pearl:** Any postmenopausal woman on tamoxifen presenting with abnormal uterine bleeding warrants urgent endometrial evaluation (transvaginal ultrasound ± endometrial biopsy). ### Lynch Syndrome and Endometrial Cancer **Key Point:** Lynch syndrome (HNPCC) is caused by germline mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2). Carriers have a 40–60% lifetime risk of endometrial carcinoma — second only to colorectal cancer in this population. Microsatellite instability (MSI) is the hallmark. ### Why Option 3 Is Incorrect Tamoxifen exerts an **estrogenic (agonistic)** effect on the endometrium, not a protective one. It increases, not decreases, endometrial carcinoma risk. The statement falsely claims a "protective estrogenic effect," which contradicts both mechanism and epidemiology. [cite:Robbins 10e Ch 22]